Neostigmina Lph (Neostigmine Bromide)

Neostigmine bromide, the active ingredient in Neostigmina Lph, is an acetylcholinesterase inhibitor presented as an oral formulation for oral use. It is employed to improve neuromuscular transmission in conditions such as myasthenia gravis, to stimulate intestinal motility after surgery, and to reverse the effects of non‑depolarizing neuromuscular blocking agents.

GNH USA supplies Neostigmina Lph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Neostigmine bromide acts as an anticholinesterase agent, enhancing acetylcholine activity at neuromuscular junctions.

Myasthenia gravis: enhances acetylcholine availability at the neuromuscular junction, leading to increased skeletal muscle strength in patients with this autoimmune disorder. Postoperative ileus: promotes intestinal peristalsis by stimulating cholinergic pathways, helping to accelerate the return of bowel function after abdominal surgery. Reversal of non‑depolarizing neuromuscular blockade: counteracts the effects of agents such as rocuronium or vecuronium, facilitating rapid recovery of respiratory and skeletal muscle activity after general anesthesia.

Neostigmine bromide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: a transient sensation of stomach upset that may be accompanied by loss of appetite. - Vomiting: occasional forceful expulsion of stomach contents, usually mild and self‑limiting. - Diarrhea: increased frequency of loose stools, often accompanied by mild abdominal discomfort. - Increased salivation: excessive production of saliva causing drooling or the need to swallow frequently. - Abdominal cramps: intermittent tightening pain in the abdomen, typically mild to moderate in intensity.

Serious or Rare Side Effects: - Cholinergic crisis: profound muscle weakness, respiratory insufficiency, and possible paralysis requiring immediate medical attention. - Bradycardia: significant slowing of the heart rate that can lead to hypotension and may need pharmacologic reversal. - Bronchospasm: constriction of the bronchial smooth muscle causing wheezing, dyspnea, and potential hypoxia.

When prescribing neostigmine bromide, clinicians should observe several safety measures to minimize risk. - Monitor respiratory function: assess for signs of respiratory depression or cholinergic crisis, especially after dose adjustments. - Adjust dose in renal impairment: reduce dosage or increase dosing interval in patients with reduced kidney function. - Avoid in mechanical intestinal obstruction: the drug can exacerbate obstruction by increasing gastrointestinal motility. - Caution in asthma or COPD: heightened cholinergic activity may provoke bronchospasm. - Review concomitant cholinergic or anticholinergic agents: co‑administration can amplify or diminish therapeutic effects. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Neostigmine bromide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other acetylcholinesterase inhibitors (e.g., pyridostigmine): additive cholinergic effects may precipitate a cholinergic crisis. - Anticholinergic drugs (e.g., atropine, scopolamine): they counteract neostigmine’s action, reducing therapeutic benefit. - Succinyl‑choline in high doses: may lead to prolonged neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): may enhance bradycardic response. - Cardiac glycosides (e.g., digoxin): increased vagal tone can raise the risk of arrhythmias. - Magnesium sulfate: potentiates neuromuscular blockade, requiring dose adjustment. - Anesthetic agents (e.g., volatile anesthetics): may modify the reversal profile and need careful monitoring.